Defining and characterizing the progression of type 2 diabetes.
Fonseca
Vivian A
VA
Tulane University Medical Center, New Orleans, Louisiana, USA. vfonseca@tulane.edu
D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D018450:Disease Progression; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000032:analysis / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism / Q000502:physiology; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000502:physiology; D009765:Obesity / Q000503:physiopathology / Q000517:prevention & control; D019518:Postprandial Period; D011236:Prediabetic State / Q000503:physiopathology*; D015430:Weight Gain
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin